Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT.

Prevymis (letermovir) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/41266751

Alexander Sebastian Hölscher; Ben-Niklas Baermann; Duyen Bao Le; Felicitas Schulz; Guido Kobbe; Inga Tometten; Jörg Timm; Kathrin Nachtkamp; Nadine Lübke; Paul Jäger; Sascha Dietrich; Stefanie Munder; Timothé Duplessix

Nov 21, 2025